Author Topic: (Abst.) Switching to Ocrevus in RRMS patients at risk of PML previously treated w/EID Tysabri  (Read 58 times)

0 Members and 1 Guest are viewing this topic.

Offline agate

  • Administrator
  • *****
  • Posts: 9816
  • MS diagnosed 1980
  • Location: Pacific Northwest
From PubMed (August 7, 2020)--"Switching to ocrelizumab in RRMS patients at risk of PML previously treated with extended interval dosing of natalizumab":


https://pubmed.ncbi.nlm.nih.gov/32749910/
MS Speaks--online for 17 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010. Glatopa (glatiramer acetate 40mg 3 times/week) since 12/16/20.

 

Related Topics

  Subject / Started by Replies Last post
0 Replies
149 Views
Last post September 16, 2016, 11:36:28 am
by agate
0 Replies
103 Views
Last post December 13, 2018, 09:02:08 pm
by agate
2 Replies
123 Views
Last post October 17, 2019, 09:09:54 pm
by agate
1 Replies
64 Views
Last post August 26, 2021, 06:56:59 pm
by agate
0 Replies
41 Views
Last post October 16, 2021, 03:53:13 pm
by agate